Partnership Opportunities CNM-Au8 is a first in class, late clinical-stage therapy targeting mitochondrial function and the NAD pathway to support neuronal survival in ALS, MS, and Parkinson’s. The emerging REPAIR-MS data on brain NAD+/NADH ratios provides a compelling case for strategic co-development or licensing deals with larger CNS players to advance indications and global rights.

Manufacturing Support Maryland-based R&D and manufacturing for CNM-Au8 indicate a need for scalable GMP supply and associated analytics, fill-finish, and packaging services as Clene progresses toward pivotal studies, creating opportunities for contract manufacturers and CROs with CNS trial experience.

Clinical Development Clene engages CROs and is active in investor events, indicating readiness for additional development partnerships and data-management collaborations to accelerate timelines and optimize regulatory strategy around CNM-Au8.

Strategic Financing With modest current revenue and a strategy focused on external partnerships and financing, Clene may seek strategic collaborations or licensing to fund expansion of CNM-Au8 programs, offering potential upside for partners through milestone or royalty based deal structures.

Indication Focus Primary addressable markets include ALS, MS, and Parkinson’s disease; opportunities to engage CNS clinics, MS centers, KOLs, and patient networks to support site networks, recruitment, advocacy, and later-stage commercialization in diverse geographies.